Journal article
Human papillomavirus vaccines: Current status and future prospects
SM Garland, JS Smith
Drugs | Published : 2010
Abstract
Worldwide, cervical cancer is the second most common cancer of women. Less-developed countries bear the greatest burden in terms of morbidity and mortality, largely due to the lack of organized screening programmes. Cervical cancer is the first cancer shown to be caused solely by virological agents: oncogenic genotypes of human papillomavirus (HPV). Two recently developed prophylactic cervical cancer vaccines, which are based on viral-like particle (VLP) technology of HPV, have the capacity to diminish a large proportion of cervical cancer cases worldwide. However, to be successful public health tools, they need to be widely implemented to the appropriate target population, preferably prior ..
View full abstractGrants
Funding Acknowledgements
We would like to acknowledge Ms Yuli Chang (University of North Carolina, Gillings School of Global Public Health) for her assistance in the preparation of this manuscript. No sources of funding were used to assist in the preparation of this review. SMG has received advisory board fees and grant support from Commonwealth Serum Laboratories and GlaxoSmithKline (GSK), and lecture and consultancy fees from Merck and Co. SMG reports having previously owned stock in Commonwealth Serum Laboratories. SMG has received grant support through her institution from Merck and Co. and GSK to perform clinical trials for HPV/cervical cancer vaccines. SMG also reports being a member of the Merck Global Advisory Board and Scientific Advisory Committee. JSS has received advisory board fees from GSK, and grant support from GSK and Merck and Co.